Tabernanthalog fumarate

Tabernanthalog (TBG) is a next-generation non-hallucinogenic compound designed to promote neuroplasticity while minimizing the safety concerns traditionally associated with classical psychedelic compounds. It is a synthetic small molecule structurally inspired by naturally occurring indole alkaloids and has shown the ability to stimulate neural growth pathways linked to cognitive flexibility and behavioral adaptation. In preclinical studies, Tabernanthalog has demonstrated potential in addressing substance use disorders and mood-related conditions by promoting structural and functional neural remodeling without producing perceptual disturbances.

Suzhou Henra Biotechnology Co., Ltd. has more than 12 years of experience in advanced pharmaceutical synthesis and specializes in the development and manufacturing of high-purity research compounds and intermediates. Our production processes are optimized for consistency, scalable output, and strict quality control standards to meet the needs of global research institutions and pharmaceutical partners.

Function: Tabernanthalog promotes neuroplasticity by activating key signaling pathways associated with neuronal growth and synaptic connectivity. It is designed to induce therapeutic neural adaptation while avoiding hallucinogenic effects commonly observed with related compounds.

Research Significance: Tabernanthalog represents an important advancement in the development of safer neuroplasticity-promoting agents. Preclinical research suggests potential applications in addiction treatment, depression, and other neuropsychiatric disorders. It remains an investigational compound and continues to be studied for safety, efficacy, and long-term therapeutic potential.